Tumor regression grading after preoperative chemoradiotherapy as prognostic factor and individual-level surrogate for disease-free survival in rectal cancer: Results of the CAO/ARO/AIO-04 multicentre, open-label, randomised, phase 3 trial

被引：0
|
作者：
Fokas, E. [1 ]
Stroebel, P. [2 ]
Fietkau, R. [3 ]
Ghadimi, M. [4 ]
Liersch, T. [4 ]
Grabenbauer, G. [5 ]
Hartmann, A. [6 ]
Kaufmann, M. [7 ]
Sauer, R. [3 ]
Graeven, U. [8 ]
Hoffmanns, H. [9 ]
Raab, H-R [10 ]
Hothorn, T. [7 ]
Wittekind, C. [11 ]
Roedel, C. [1 ]
机构：
[1] Goethe Univ Frankfurt, Klin Strahlentherapie & Onkol, Frankfurt, Germany
[2] Univ Klinikum Gottingen, Inst Pathol, Gottingen, Germany
[3] Univ Erlangen Nurnberg, Klin Strahlentherapie & Radioonkol, Erlangen, Germany
[4] Univ Klinikum Gottingen, Klin Allgemeinchirurg, Gottingen, Germany
[5] DiaCura & Klinikum Coburg, Klin Strahlentherapie & Radioonkol, Coburg, Germany
[6] Univ Klinikum Erlangen Nurnberg, Inst Pathol, Erlangen, Germany
[7] Univ Zurich, Epidemiol Biostat & Prevent Inst, Zurich, Switzerland
[8] Kliniken Maria Hilf GmbH, Klin Hamatol Onkol, Monchengladbach, Germany
[9] Kliniken Maria Hilf GmbH, Klin Strahlentherapie, Monchengladbach, Germany
[10] Univ Klinikum Oldenburg, Klin Allgemeinchirurg, Oldenburg, Germany
[11] Univ Klinikum Leipzig, Inst Pathol, Leipzig, Germany
来源：
STRAHLENTHERAPIE UND ONKOLOGIE | 2017年 / 193卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V11-1
引用
收藏
页码：S31 / S31
页数：1
相关论文
共 25 条
  • [1] Neoadjuvant rectal score as individual-level surrogate for disease-free survival in rectal cancer in the CAO/ARO/AIO-04 randomized phase 3 trial
    Fokas, E.
    Fietkau, R.
    Hartmann, A.
    Hohenberger, W.
    Ghadimi, M.
    Liersch, T.
    Stroebel, P.
    Grabenbauer, G.
    Hofheinz, R. -D.
    Wittekind, C.
    Sauer, R.
    Kaufmann, M.
    Hothorn, T.
    Roedel, C.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2018, 194 : S22 - S22
  • [2] Prognostic significance of tumor regression grading following preoperative chemoradiotherapy for rectal cancer in the CAO/ARO/AIO-04 randomised trial
    Roedel, C.
    Fietkau, R.
    Hohenberger, W.
    Hothorn, T. H.
    Wolff, H. A.
    Stroebel, P.
    Hess, C. F.
    Graeven, U.
    Fokas, E.
    Arnold, D.
    Liersch, T.
    Ghadimi, M.
    Sauer, R.
    Wittekind, C.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2015, 191 : S4 - S5
  • [3] Neoadjuvant rectal score as individual-level surrogate for disease-free survival in rectal cancer in the CAO/ARO/AIO-04 randomized phase III trial
    Fokas, E.
    Fietkau, R.
    Hartmann, A.
    Hohenberger, W.
    Gruetzmann, R.
    Ghadimi, M.
    Liersch, T.
    Stroebel, P.
    Grabenbauer, G. G.
    Graeven, U.
    Hofheinz, R-D
    Koehne, C-H
    Wittekind, C.
    Sauer, R.
    Kaufmann, M.
    Hothorn, T.
    Roedel, C.
    ANNALS OF ONCOLOGY, 2018, 29 (07) : 1521 - 1527
  • [4] Tumor Regression Grading After Preoperative Chemoradiotherapy as a Prognostic Factor and Individual-Level Surrogate for Disease-Free Survival in Rectal Cancer
    Fokas, Emmanouil
    Stroebel, Philipp
    Fietkau, Rainer
    Ghadimi, Michael
    Liersch, Torsten
    Grabenbauer, Gerhard G.
    Hartmann, Arndt
    Kaufmann, Marco
    Sauer, Rolf
    Graeven, Ullrich
    Hoffmanns, Hans
    Raab, Hans-Rudolf
    Hothorn, Torsten
    Wittekind, Christian
    Roedel, Claus
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2017, 109 (12):
  • [5] NAR score as surrogate for disease-free survival in the CAO/ARO/AIO-04 phase 3 rectal cancer trial
    Fokas, E.
    Fietkau, R.
    Hartmann, A.
    Hohenberger, W.
    Gruetzmann, R.
    Ghadimi, M.
    Liersch, T.
    Stroebel, P.
    Grabenbauer, G.
    Wittekind, C.
    Sauer, R.
    Kaufmann, M.
    Hothorn, T.
    Roedel, C.
    RADIOTHERAPY AND ONCOLOGY, 2018, 127 : S142 - S142
  • [6] Tumor Regression Grading in the CAO/ARO/AIO-04 phase 3 trial in locally advanced rectal carcinoma
    Fokas, E.
    Ghadimi, M.
    Fietkau, R.
    Stroebel, P.
    Hartmann, A.
    Sauer, R.
    Liersch, T.
    Hothorn, T.
    Wittekind, C.
    Roedel, C.
    RADIOTHERAPY AND ONCOLOGY, 2017, 123 : S170 - S171
  • [7] Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial
    Roedel, Claus
    Graeven, Ullrich
    Fietkau, Rainer
    Hohenberger, Werner
    Hothorn, Torsten
    Arnold, Dirk
    Hofheinz, Ralf-Dieter
    Ghadimi, Michael
    Wolff, Hendrik A.
    Lang-Welzenbach, Marga
    Raab, Hans-Rudolf
    Wittekind, Christian
    Stroebel, Philipp
    Staib, Ludger
    Wilhelm, Martin
    Grabenbauer, Gerhard G.
    Manns, Hans Hoff
    Lindemann, Fritz
    Schlenska-Lange, Anke
    Folprecht, Gunnar
    Sauer, Rolf
    Liersch, Torsten
    Sauer, R.
    Hohenberger, W.
    Fietkau, R.
    Lahmer, G.
    Golcher, H.
    Klautke, G.
    Hartmann, A.
    Rau, T.
    Keilholz, L.
    Henneking, K.
    Muehldorfer, S.
    Klein, S.
    Stolte, M.
    Staar, S.
    Lehnert, T.
    Hertenstein, B.
    Freys, S. M.
    Pflueger, K.-H.
    Sendt, W.
    Teyssen, S.
    Latz, D.
    Leibl, B. J.
    Matek, W.
    Grabenbauer, G. G.
    Alfrink, M.
    Kreczy, A.
    Strobel, G. F.
    Düwel, H.-J.
    LANCET ONCOLOGY, 2015, 16 (08): : 979 - 989
  • [8] Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial
    Roedel, Claus
    Liersch, Torsten
    Becker, Heinz
    Fietkau, Rainer
    Hohenberger, Werner
    Hothorn, Torsten
    Graeven, Ullrich
    Arnold, Dirk
    Lang-Welzenbach, Marga
    Raab, Hans-Rudolf
    Suelberg, Heiko
    Wittekind, Christian
    Potapov, Sergej
    Staib, Ludger
    Hess, Clemens
    Weigang-Koehler, Karin
    Grabenbauer, Gerhard G.
    Hoffmanns, Hans
    Lindemann, Fritz
    Schlenska-Lange, Anke
    Folprecht, Gunnar
    Sauer, Rolf
    Lahmer, G.
    Golcher, H.
    Klautke, G.
    Hartmann, A.
    Rau, T.
    Keilholz, L.
    Henneking, K.
    Muehldorfer, S.
    Klein, S.
    Stolte, M.
    Staar, S.
    Lehnert, T.
    Hertenstein, B.
    Freys, S. M.
    Pflueger, K.-H.
    Sendt, W.
    Teyssen, S.
    Latz, D.
    Leibl, B. J.
    Matek, W.
    Grabenbauer, G. G.
    Alfrink, M.
    Kreczy, A.
    Strobel, G. F.
    Duewel, H.-J.
    Bechstein, W. O.
    Gog, C.
    Boettcher, H.-D.
    LANCET ONCOLOGY, 2012, 13 (07): : 679 - 687
  • [9] Tumor Regression Grading After Preoperative Chemoradiotherapy for Locally Advanced Rectal Carcinoma Revisited: Updated Results of the CAO/ARO/AIO-94 Trial
    Fokas, Emmanouil
    Liersch, Torsten
    Fietkau, Rainer
    Hohenberger, Werner
    Beissbarth, Tim
    Hess, Clemens
    Becker, Heinz
    Ghadimi, Michael
    Mrak, Karl
    Merkel, Susanne
    Raab, Hans-Rudolf
    Sauer, Rolf
    Wittekind, Christian
    Roedel, Claus
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15) : 1554 - 1562
  • [10] Can local excision be safely recommended in patients with ypT0-2 rectal cancer after chemoradiotherapy? Clinicopathological results of the CAO/ARO/AIO-94 and CAO/ARO/AIO-04 randomized phase 3 trials
    von den Gruen, Mueller J.
    Hartmann, A.
    Fietkau, R.
    Ghadimi, M.
    Liersch, T.
    Stroebel, P.
    Sauer, R.
    Roedel, C.
    Fokas, E.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2018, 194 : S14 - S15
123